EVAX logo

EVAX Evaxion Biotech A/S

NASDAQ Capital Market · Biotechnology · Healthcare

$2.25
+0.22 (+10.84%)

Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA…

Market Cap: $14.21Mevaxion.ai

Price

No data yet.

Social Signal Score

57
5d
57
3 mentions
—
30d
56
7 mentions
—
60d
56
7 mentions
—
90d
58
8 mentions
—
news: 8

Analyst Ratings

4 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 0Sell 0Strong Sell 0
Avg price target$9.5+322.2%
Low $9Median $9.5High $10
Current Consensus

Revenue

$0.00
$0.00$2.50M$4.99M$7.49M
Dec 2019Jun 2026

Analyst Estimates

FY2025
$-0.45
$-0.45–$-0.45
1 analysts
FY2026
$-0.04
$-0.04–$-0.04
1 analysts
FY2027
$-0.01
$-0.01–$-0.01
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Helen Katrina Tayton-Martin
Sector
Healthcare
Industry
Biotechnology
Employees
46
Beta
0.27
Country
DK
Piotroski score
5 / 9 (Middling)
Altman Z-score
-9.30
evaxion.ai